Figure A2.
Engineered LMP1 vaccines enhance cellular immunity. The LMP1 antigen was truncated at the N-terminal, received an IgE leader sequence, and had tetanus toxoid added to its sequence. Splenocytes were stimulated with the 5 strongest MHC class I peptides to LMP1, as predicted in silico, after C57BL/6 mice were vaccinated. (A) IFNγ ELISPOT results showing an average of 59 sfu for LMP1tt30. (B) Flow cytometry data showing improved CD8 responses following plasmid engineering.